Sygnature Discovery has announced a strategic brand relaunch, including a new website.
The company hopes that the relaunch will "cement its position as a global drug discovery partner."
For more than 20 years, Sygnature has established a strong reputation for delivering high-quality candidates. Ongoing investments and strategic acquisitions have allowed the company to support customers throughout the entire drug discovery process, from target identification to candidate nomination.
The company is uniquely positioned as the only CRO offering full Design, Make, Test, Analyse (DMTA) capabilities under one roof in both North America and Europe.
Sygnature is now targeting increased awareness and global market share.
In recent years, Sygnature has integrated several complementary businesses, enhancing its scientific breadth, scale, and geographic reach.
Today, the company offers a wide range of capabilities, including bioscience, protein science, structural biology, synthetic and medicinal chemistry, computer-aided drug design, drug metabolism and pharmacokinetics (DMPK), in vivo pharmacology, as well as formulation and delivery.
These services are provided by co-located, multidisciplinary teams.
"We've grown significantly in scale and capability during the past two decades," said Dr Simon Hirst, CEO of Sygnature Discovery.
"Biotech and pharma companies are facing volatile investment conditions, tighter timelines and rising costs. Our truly integrated approach is built around helping customers navigate that reality — whether they're outsourcing a whole programme or need expert input in a single discipline."
"By bringing together multidisciplinary expertise in co‑located teams, supported by AI and automation, we help customers move faster and improve the quality of their decisions."
"Across Europe and North America, we act as an extension of our customers' teams, delivering a service they can trust."